A. Raza

A. Raza, V. Shetty, H. Qawi, 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Extensive apoptosis of bone marrow cells as evaluated by the in situ end‐labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

T. Economopoulos, S. Raptis, A. Raza, 1999, European journal of haematology.

AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN REMISSION

H. Preisler, A. Raza, 1987 .

Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T‐cell expansion

B. Woda, A. Raza, N. Galili, 2007, British journal of haematology.

Combination of classical and interphase cytogenetics to investigate the biology of myeloid disorders: detection of masked monosomy 7 in AML.

A. Raza, A. Srivastava, B. Lampkin, 1993, Leukemia research.

Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine.

P. Venugopal, M. Showel, A. Raza, 1997, Experimental hematology.

A t(1;11) in acute nonlymphocytic leukemia FAB type M4.

A. Raza, S. Sait, A. Sandberg, 1987, Cancer genetics and cytogenetics.

Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts.

A. Raza, S. Sait, A. Sandberg, 1987, Cancer genetics and cytogenetics.

A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31

Z. Arbieva, A. Raza, S. Horrigan, 2001, Oncogene.

Kinetic Resistance, Regrowth Resistance, and Multidrug Resistance in the Treatment of Acute Myelogenous Leukemia (AML)

H. Preisler, A. Raza, 1996 .

DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia

A. Raza, S. Mukherjee, M. Ewalt, 2011, Blood cancer journal.

Neoplastic Progression of the Myeloid Leukemias

H. Preisler, A. Raza, 1989 .

Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients

A. Raza, N. Galili, S. Mundle, 2002, British journal of haematology.

Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group.

A. Raza, 2001, Blood.

Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia

H. Preisler, A. Raza, J. Kirshner, 1985, American journal of hematology.

Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).

J. Rowley, M. L. Le Beau, A. Raza, 2007, Cancer research.

Leukemia with inv ( 16 )-SMMHC in Acute Myelogenous β ( p 15 ) by CBF INK 4 b Methylation-Independent Silencing of the Tumor Suppressor

J. Rowley, M. L. Beau, A. Raza, 2007 .

Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML)

A. Raza, N. Galili, E. Devemy, 2008, Journal of hematology & oncology.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

E. Vellenga, D. Steensma, P. Fenaux, 2019, HemaSphere.

A t (11;21) (13;q22) in Ph-positive chronic myelogenous leukemia.

A. Raza, S. Sait, A. Sandberg, 1988, Cancer genetics and cytogenetics.

Two different “tales” of ATG7: Clinical relevance to myelodysplastic syndromes

A. Raza, A. Ali, 2016, Molecular & cellular oncology.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Jason Gotlib, Moshe Talpaz, J. Dipersio, 2012, The New England journal of medicine.

Improved rapid autoradiography with elimination of background

H. Preisler, A. Raza, C. Spiridonidis, 1985, Cell biochemistry and function.

Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1

P. Venugopal, H. Preisler, A. Raza, 2000, British journal of haematology.

Thrombocytopenia Predicts for Poor Survival In Patients with Lower Risk Myelodysplastic Syndromes (MDS)

A. Raza, N. Galili, Raymond Cruz, 2010 .

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Scott E. Smith, D. Mahadevan, A. Raza, 2010 .

P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study

J. Reeves, J. Bennett, G. Dewald, 2005 .

The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia.

R. Larson, G. Tricot, H. Preisler, 1993, European journal of cancer.

Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

R. Larson, R. Priore, K. Rai, 1984, British journal of haematology.

Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients.

A. Raza, S. Mukherjee, A. Eisenberger, 2013 .

Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia.

H. Preisler, V. Gopal, A. Raza, 1995, Leukemia research.

The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.

R. Larson, G. Tricot, G. Browman, 1994, Leukemia & lymphoma.

Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements

G. Tricot, R. Priore, K. Rai, 1986, British journal of haematology.

Presence of activation-related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromes.

P. Venugopal, A. Raza, E. Afenya, 2001, Cancer letters.

A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

L. Silverman, S. Parmar, H. Kantarjian, 2008 .

Tetrasomy of chromosome 8: an interesting and rare cytogenetic phenomenon in acute nonlymphocytic leukemia.

A. Raza, A. Sandberg, S. J. Jani Sait, 1987, Cancer genetics and cytogenetics.

myelogenous leukemia (letter) Interleukin-1 beta expression and treatment outcome in acute

R. Larson, G. Browman, H. Preisler, 2011 .

Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia

R. Larson, G. Browman, H. Preisler, 1993, American journal of hematology.

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure

F. Ravandi, A. Rastogi, A. Raza, 2013, Cytometry. Part B, Clinical cytometry.

Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia.

H. Preisler, A. Raza, S. Banavali, 1994, European journal of cancer.

In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.

H. Preisler, A. Raza, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Detection of monosomy 7 in interphase cells of patients with myeloid disorders

T. Cremer, L. Manuelidis, A. Raza, 1990, American journal of hematology.

The Premyelodysplastic State and the Secondary Hematologic Disorders

H. Preisler, S. Bi, Jie Yang, 1998 .

Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

A. Raza, N. Galili, M. Mehdi, 2008, Cancer.

Analysis of cell cycle characteristics and course of the disease in ANLL

H. Preisler, A. Raza, Y. Maheshwari, 1987, American journal of hematology.

Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia

A. Raza, T. D. Witte, R. Raymakers, 1998, Leukemia.

Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis

H. Preisler, A. Raza, S. Shott, 1995, American journal of hematology.

Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients.

R. Larson, H. Preisler, V. Gopal, 1993, Leukemia & lymphoma.

Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia

R. Larson, G. Browman, H. Preisler, 1993, American journal of hematology.

Contribution of in vivo proliferation/differentiation studies toward the development of a combined functional and morphologic system of classification of neoplastic diseases

H. Preisler, A. Raza, B. Lampkin, 1992, Cancer.

Cell Cycle Parameters as Biological Predictors of Prognosis in AML: A Review and Update of Cell Cycle Kinetics and Remission Induction/Duration in Acute Leukemia

H. Preisler, A. Raza, S. Bokhari, 1992 .

Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia

Naveed Yousuf, Richard Larson, R. Larson, 1991, British journal of haematology.

Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study.

R. Day, G. Browman, H. Preisler, 1990, Blood.

A comparison of the rate of DNA synthesis in myeloblasts from peripheral blood and bone marrows of patients with acute nonlymphocytic leukemia.

A. Raza, Z. Yasin, C. Grande, 1988, Experimental cell research.

A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.

H. Preisler, A. Raza, N. Mandava, 1987, Leukemia research.

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

P. Venugopal, A. Raza, J. Zeldis, 2001, Blood.

Decitabine improves patient outcomes in myelodysplastic syndromes

John M Bennett, J. Issa, Lanlan Shen, 2006, Cancer.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

J. Reeves, H. Deeg, P. Greenberg, 2008, Blood.

Comparison ofin vitro assays for detecting subpopulations of P388 leukemic cells resistant to AraC

H. Preisler, A. Raza, A. Raza, 1984, Medical oncology and tumor pharmacotherapy.

Survey and evaluation of mutations in the human KLF1 transcription unit

J. Bieker, A. Raza, J. Crispino, 2018, Scientific Reports.

MicroRNAs in myeloproliferative neoplasms

A. Raza, C. Cardozo, H. Zhan, 2013, British journal of haematology.

Current View of miRNA with Tumor Suppressor Function, Exploring MDS and AML as Models

A. Raza, N. Galili, A. Ali, 2014 .

U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation.

Michael R. Green, Sung Mi Park, L. Zhu, 2016, Molecular cell.

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Michelle C. Chen, B. Ebert, M. Fleming, 2016, Cancer cell.

Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia

A. Raza, S. Mundle, 2001, Cancer Treatment and Research.

Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.

V. Zota, B. Woda, A. Raza, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.

S. K. Zaidi, G. Stein, J. Lian, 2009, Cancer research.

Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.

A. Raza, N. Galili, 2009, Best practice & research. Clinical haematology.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

P. Greenberg, J. Bennett, R. Stone, 2006, The New England journal of medicine.

A Pluralistic Approach to the Study of Myelodysplastic Syndromes: Evolving Pathology of the Seed via the Soil

A. Raza, N. Galili, Raymond Cruz, 2011 .

The biology of myelodysplastic syndromes: unity despite heterogeneity

A. Raza, N. Galili, S. Mukherjee, 2010, Hematology reports.

Defective ribosome biogenesis in myelodysplastic syndromes

A. Raza, N. Galili, Samir Ahmed Qasim, 2009, Haematologica.

Four cases with complex Philadelphia translocations, including one with appearance de novo of a "masked" Ph.

H. Preisler, A. Raza, A. Sandberg, 1987, Cancer genetics and cytogenetics.

Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts

R. Rabadán, J. Teruya-Feldstein, G. Bhagat, 2014, Nature.

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes

R. Rabadán, J. Manley, X. An, 2020, Proceedings of the National Academy of Sciences.

Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.

R. Priore, H. Preisler, Y. Rustum, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.

R. Larson, G. Browman, H. Preisler, 1993, Leukemia & lymphoma.

Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.

L. Booker, G. Browman, H. Preisler, 1984, European journal of cancer & clinical oncology.

Relationship between the per cent of marrow cells in S phase and the outcome of remission‐induction therapy for acute nonlymphocytic leukaemia

G. Browman, H. Preisler, A. Raza, 1984, British journal of haematology.

Remission Duration in Acute Nonlymphocytic Leukemia: Practical and Theoretical Considerations

G. Browman, H. Preisler, A. Raza, 1984 .

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

B. Ebert, T. Jacks, D. Gilliland, 2011, Blood.

Detection of BrdU in the regenerating bone marrow cells of a patient with AML.

H. Preisler, A. Raza, S. Gezer, 1989, Leukemia research.

Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes.

P. Venugopal, I. Janssen, G. Saberwal, 2003, Journal of hematotherapy & stem cell research.

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

Pablo Tamayo, Benjamin L Ebert, Todd R Golub, 2008, PLoS medicine.

Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase.

H. Handa, H. Preisler, U. Hegde, 1997, Leukemia research.

Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes

P. Venugopal, A. Raza, N. Galili, 2004, Leukemia & lymphoma.

The role of emerging technologies in the diagnosis and staging of neoplastic diseases

H. Preisler, A. Raza, 1992, Cancer.

Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification

B. Woda, A. Raza, Sa A. Wang, 2008, Modern Pathology.

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes

A. Raza, N. Galili, 2012, Nature Reviews Cancer.

Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.

R. Rabadán, J. Manley, A. Raza, 2019, Molecular cell.

MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia

R. Day, I. Pastan, R. Larson, 1990, British journal of haematology.

Chromosomes and causation of human cancer and leukemia. LIV. Near-tetraploidy in acute leukemia.

H. Preisler, A. Raza, A. Sandberg, 1985, Cancer genetics and cytogenetics.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features

B. Woda, A. Raza, N. Galili, 2006, Leukemia.

Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.

H. Preisler, A. Raza, R. Borok, 1995, Blood.

Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.

P. Venugopal, A. Raza, R. Huang, 2000, Blood.

Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.

R. Larson, H. Preisler, A. Raza, 1992, Blood.

Anti‐TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

A. Raza, Azra Raza, 2000, Microscopy research and technique.

Marrow cytokine transcripts and the secondary hematologic disorders.

H. Preisler, S. Bi, A. Raza, 1999, Leukemia and Lymphoma.

Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

T. Shanafelt, N. Kay, A. Raza, 2007, Leukemia research.

Patients with Myeloid Leukemias Expression of Nucleolar Antigen p 145 in Bone Marrow Cells of Updated

J. Freeman, A. Raza, S. Imren, 2006 .

Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias.

J. Freeman, A. Raza, S. Imren, 1989, Cancer research.

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

INCREASED MACROPHAGES, HIGH SERUM M‐CSF AND LOW SERUM CHOLESTEROL IN MYELODYSPLASIA AND KAWASAKI DISEASE

A. Raza, V. Shetty, Krishman Allampallam, 1999, British journal of haematology.

Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia.

M. Baccarani, H. Preisler, A. Raza, 1993, Leukemia & lymphoma.

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts.

J. Teruya-Feldstein, G. Bhagat, D. Dempster, 2014, Blood.

The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.

C. Gross, Xiao Xu, Xiaomei Ma, 2012, Leukemia research.

Increased incidence of mitochondrial cytochrome c‐oxidase gene mutations in patients with myelodysplastic syndromes

G. Saberwal, A. Raza, N. Galili, 2002, British journal of haematology.

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.

R. Larson, H. Preisler, A. Raza, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous remission in acute nonlymphocytic leukemia.

H. Preisler, A. Raza, I. Rakowski, 1985, New York state journal of medicine.

Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes.

P. Venugopal, A. Raza, S. Gregory, 1999, Cancer letters.

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes

P. Venugopal, A. Raza, K. Allampallam, 2001, British journal of haematology.

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.

C. Gross, Xiaomei Ma, A. Raza, 2011, Leukemia research.

The treatment of patients with acute nonlymphocytic leukemia in remission.

G. Browman, Y. Rustum, H. Preisler, 1985, Seminars in oncology.

Cell cycle studies in acute myelogenous leukemia.

H. Preisler, A. Raza, 1992, Leukemia.

Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions.

H. Preisler, A. Raza, 1992, Leukemia.

Effects of rGM‐CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA

H. Preisler, A. Raza, M. Yin, 1991, Cell biochemistry and function.

Treatment of myeloid blastic crisis of chronic myelogenous leukemia.

H. Preisler, A. Raza, R. Weiner, 1984, Cancer treatment reports.

Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia

R. Larson, G. Browman, H. Preisler, 2004, Cancer Chemotherapy and Pharmacology.

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

Scott E. Smith, J. Keck, J. Lancet, 2009, Blood.

Assessment of cell-cycle effects of cytokines in vivo.

H. Preisler, A. Raza, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study

R. Larson, R. Priore, G. Browman, 1989, British journal of haematology.

Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls.

Olga Pozdnyakova, Sa A Wang, B. Smith, 2008, Leukemia research.

The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure

R. Day, R. Larson, G. Browman, 1991, British journal of haematology.

Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.

R. Larson, G. Tricot, H. Preisler, 1991, Leukemia research.

Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside

H. Preisler, A. Raza, M. Barcos, 1985, Medical oncology and tumor pharmacotherapy.

Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody

R. Larson, J. Bennett, G. Browman, 1991 .

Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia: Directions For The New Millennium

A. Raza, S. Mundle, 2012 .

Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies

Hui Wang, A. Raza, A. Ali, 2019, Proceedings of the National Academy of Sciences.

c-myc and c-myb expression in acute myelogenous leukemia.

R. Larson, G. Tricot, H. Preisler, 1992, Leukemia research.

Complex cytogenetic changes in Ph-negative chronic myelogenous leukemia.

A. Raza, S. Sait, A. Sandberg, 1988, Cancer genetics and cytogenetics.

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

A. Letai, J. Scandura, A. Raza, 2014 .

The study of acute leukemia cells by means of acridine orange staining and flow cytometry.

H. Preisler, V. Gopal, A. Raza, 1994, Leukemia & lymphoma.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

G. Abel, Yolanda Martins, D. Steensma, 2016, Haematologica.

A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

M. Tallman, G. Borthakur, D. DeAngelo, 2014, PloS one.

Biologic characteristics of 164 patients with myelodysplastic syndromes.

P. Venugopal, A. Raza, S. Mundle, 1999, Leukemia and Lymphoma.

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

J. Dipersio, M. Arcasoy, H. Kantarjian, 2013 .

Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.

J. Dipersio, M. Arcasoy, H. Kantarjian, 2012 .

Effects of Vitamin-A on Growth Traits, Immunoregulatory Organs and Immune Response in Broiler Chicken

A. Raza, Saeed R. Khan, M. Saeed, 1997 .

A permanent method of detecting SCE by immunofluorescence using monoclonal anti-BrdU antibodies.

H. Preisler, A. Raza, A. Block, 1985, Cancer genetics and cytogenetics.

An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system.

H. Preisler, A. Raza, 1993, Leukemia & lymphoma.

[Treatment of acute nonlymphocytic leukemia].

A. Raza, K. Preĭsler, 1991, Gematologiia i transfuziologiia.

Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients

P. Venugopal, A. Raza, S. Gregory, 2000, Hematology.

Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes.

A. Raza, M. Mushtaq, A. Ali, 2016 .

A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.

M. Berger, G. Borthakur, A. Raza, 2014, Clinical lymphoma, myeloma & leukemia.

Translocation t(6;9)(p23;q34) in acute nonlymphocytic leukemia. Two new patients without increased bone marrow basophils.

A. Raza, A. Sandberg, J. Rowe, 1988, Cancer genetics and cytogenetics.

Improvement in cytopenias of patients with myelodysplastic syndromes (Mds) In response to thalidomide

P. Venugopal, A. Raza, P. Meyer, 2000 .

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

E. Vellenga, D. Steensma, P. Fenaux, 2019, Blood.

by osteoblasts Inhibition of leukemia cell engraftment and disease progression in mice

J. Teruya-Feldstein, G. Bhagat, D. Dempster, 2014 .

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

M. McKeown, J. Cortes, D. Steensma, 2017 .

Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)

A. Raza, A. Ali, J. Jurcic, 2023, Medical Oncology.

Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies

Hui Wang, A. Raza, A. Ali, 2019, Proceedings of the National Academy of Sciences.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

P. Fenaux, A. Raza, M. Sekeres, 2022, Blood.

The treatment of acute myelocytic leukemia in patients 30 years of age and younger

G. Browman, H. Preisler, A. Raza, 1982, American journal of hematology.

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

E. Vellenga, P. Fenaux, S. Thépot, 2021, Blood.

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

J. Mesirov, P. Tamayo, O. Botvinnik, 2012, Journal of Hematology & Oncology.

Coordinate loss of a microRNAand protein-coding gene cooperate in the pathogenesis of 5qsyndrome

B. Ebert, T. Jacks, D. Gilliland, 2016 .

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5 q-syndrome RUNNING TITLE : COOPERATIVE LOSS OF MIR-145 AND RPS 14 IN 5 Q-MDS

B. Ebert, T. Jacks, D. Gilliland, 2011 .

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

J. Cortes, J. Liesveld, A. Raza, 2018, Blood.

The Treatment of Acute Leukemia in Patients 30 Younger M yelocyt ic Years of Age and

G. Browman, H. Preisler, A. Raza, 2006 .

Autologous bone marrow transplantation for acute leukemia in remission.

H. Preisler, A. Raza, 1987, British journal of haematology.

A. Jankowska, J. Maciejewski, Y. Saunthararajah, 2012, Cancer.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

T. Jacks, D. Gilliland, A. Nonami, 2011, Blood.

Clinical effect of point mutations in myelodysplastic syndromes.

D. Neuberg, B. Ebert, B. Nilsson, 2011, The New England journal of medicine.

Utility and sensitivity of anti BrdU antibodies in assessing S‐phase cells compared to autoradiography

H. Preisler, A. Raza, K. Ucar, 1985, Cell biochemistry and function.

ON BAYESIAN ANALYSIS OF THE EXPONENTIAL SURVIVAL TIME ASSUMING THE EXPONENTIAL CENSOR TIME

A. Raza, M. Saleem, 2011 .

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

Scott E. Smith, J. Keck, J. Lancet, 2009, Blood.

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Michelle C. Chen, B. Ebert, M. Fleming, 2016, Cancer cell.

Immunomodulatory drugs in myelodysplastic syndromes

A. Raza, N. Galili, 2006, Expert opinion on investigational drugs.

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

R. Kurzrock, H. Kantarjian, R. Kerstens, 2007, Blood.